# uniQure N.V. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/uniQure N.V.). ## Overview uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for severe genetic and other diseases. Its business centers on adeno-associated virus (AAV) gene therapy programs, including clinical-stage candidates and a marketed therapy, with operations spanning the United States and Europe. ## Products & services • Gene therapy product development and clinical trials • AMT-130 for Huntington’s disease • HEMGENIX® commercialization support and royalty income • Other AAV-based pipeline programs such as AMT-191 and AMT-162 - **Clinical-stage gene therapy programs** (70%) — Research, development, and clinical testing of AAV-based therapies for rare and severe diseases. - **Commercial royalty and license revenue** (20%) — Royalty and license income tied to HEMGENIX® sales under collaboration arrangements. - **Collaboration and development services** (10%) — Services performed for partners under development and supply agreements. - Gene therapy product development and clinical trials - AMT-130 for Huntington’s disease - HEMGENIX® commercialization support and royalty income - Other AAV-based pipeline programs such as AMT-191 and AMT-162 ## Customers uniQure’s direct customers are primarily pharmaceutical partners and collaborators, while the eventual end users are patients treated through healthcare providers. In its commercial model, third-party payers, physicians, and specialty treatment centers are important because they influence adoption and reimbursement for approved therapies. The company also relies on contract manufacturing and development counterparties to execute clinical and supply activities. - **Pharmaceutical collaboration partners** (primary) — Partners like CSL Behring that buy development, supply, or royalty-linked rights under collaboration agreements. - **Healthcare providers and physicians** (primary) — Specialists who recommend and administer gene therapies once products are approved. - **Third-party payers** (primary) — Insurers and reimbursement bodies that influence access and commercial uptake of approved therapies. - **Patients with rare genetic diseases** (primary) — Patients targeted by the company’s gene therapy pipeline, including Huntington’s disease and other rare disorders. - **Clinical and manufacturing service providers** (secondary) — CROs, CMOs, and other vendors that conduct trials, manufacture materials, and support development. - Pharmaceutical partners such as CSL Behring for collaboration and royalties - Healthcare providers and physicians who prescribe approved therapies - Third-party payers that determine reimbursement and access - Patients with rare or severe genetic diseases as end beneficiaries - CROs, CMOs, and other service providers that support trials and supply ## Geography uniQure operates across the United States and Europe, where it runs clinical development and supports partner-related activities. Its reporting also reflects meaningful euro and U.S. dollar exposure, indicating a cross-border operating structure and foreign exchange sensitivity. The company’s clinical programs, regulatory interactions, and supply arrangements are tied to both U.S. and European markets. - Operations and clinical trials span the United States and Europe - U.S. regulatory and reimbursement systems are central to commercialization - European operations create euro-denominated cost and cash exposure - Cross-border clinical work increases regulatory and logistics complexity - Foreign exchange movements affect reported results and liquidity ## Strategy uniQure’s strategy is centered on advancing its lead gene therapy programs through clinical development and regulatory review, with AMT-130 a key focus. It also seeks to monetize approved or partnered assets through collaboration, license, and royalty arrangements while using external service providers for development and manufacturing execution. The company’s direction depends on converting scientific data into regulatory and commercial milestones. - **Advance AMT-130 for Huntington’s disease** (short-term) — The lead program is central to the company’s clinical and commercial value creation. - **Expand and progress the gene therapy pipeline** (medium-term) — A broader pipeline reduces dependence on a single asset and supports long-term optionality. - **Monetize partnered assets and royalty streams** (medium-term) — Partnered programs can generate non-dilutive revenue and validate the platform. - **Manage external execution risk** (short-term) — Clinical and manufacturing outcomes depend heavily on third-party service providers. - Advance AMT-130 through late-stage clinical development - Build value from AAV gene therapy pipeline assets - Monetize partnered programs through royalties and licenses - Use third-party providers for trials, manufacturing, and development - Pursue regulatory designations that can support development paths ## Risks uniQure is highly dependent on the clinical success of AMT-130, so setbacks in efficacy, safety, manufacturing, or regulatory review could materially impair the business. The company also faces execution risk from third-party vendors, product liability exposure, and healthcare compliance obligations tied to commercialization and payer relationships. As a cross-border biotech, it is exposed to foreign exchange volatility and complex data privacy, regulatory, and reimbursement regimes. - **Dependence on AMT-130 clinical success** [critical] — The lead program is a major driver of future value, so failure would materially impair prospects. - **Third-party execution and data quality risk** [high] — CROs and other vendors conduct key studies and supply activities outside direct employee control. - **Product liability and patient safety claims** [high] — Clinical and commercial gene therapies can trigger claims related to adverse events or administration procedures. - **Healthcare compliance and anti-bribery risk** [medium] — Commercialization involves physicians, payers, and third parties subject to U.S. and international healthcare laws. - **Foreign exchange volatility** [medium] — The company holds and transacts in euros and U.S. dollars, creating translation and remeasurement effects. - AMT-130 clinical failure would materially weaken the core value proposition - Third-party vendors can delay trials or compromise data quality - Gene therapy products carry product liability and safety risk - Healthcare anti-bribery and fraud laws can constrain commercialization - Euro/U.S. dollar exposure creates foreign exchange volatility ## Accounting uniQure’s reporting is shaped by collaboration revenue, license revenue, and the timing of contract manufacturing recognition, which can create quarter-to-quarter volatility. The company also uses fair value estimates for items such as pre-funded warrants and contingent consideration, while foreign currency remeasurement affects reported gains and losses. Investors should also watch how development-stage costs, royalty arrangements, and any impairment or estimate changes flow through the income statement. - **License and collaboration revenue recognition** — Can cause uneven quarterly revenue and comparability issues - **Contract manufacturing accounting** — Affects historical revenue mix and gross margin presentation - **Fair value of pre-funded warrants** — Can materially affect reported loss in a period - **Foreign currency remeasurement** — Creates gains or losses unrelated to core operating performance - **Contingent consideration** — Valuation changes can affect liabilities and earnings - License revenue is recognized from royalty payments when earned - Collaboration revenue depends on satisfaction of performance obligations - Contract manufacturing revenue ended after the Lexington transaction - Fair value changes on warrants can create non-operating volatility - Foreign currency remeasurement affects reported gains and losses - Contingent consideration requires judgment and valuation estimates --- *Last updated: 2026-04-29T05:12:40.135038+00:00*